Beta 2 microglobulin (B2M) is a small protein found on the surface of nearly every cell in your body. It plays a structural role in your immune system and is shed into the blood at a steady rate, making it a useful marker for kidney function, certain cancers, and inflammatory conditions. If your doctor ordered a B2M test, they’re likely looking at one of these areas.
What B2M Does in the Body
Every cell with a nucleus displays molecules on its surface that help your immune system distinguish “self” from “foreign.” These surface molecules, called MHC class I antigens, are made of two parts: a heavy chain unique to each person and a light chain that’s the same across all of them. That light chain is beta 2 microglobulin. Without B2M stabilizing the structure, the heavy chain can’t fold correctly or reach the cell surface, and immune cells can’t do their job of scanning for infections or abnormal cells.
B2M is constantly produced and released into the bloodstream as cells turn over. The protein is tiny, roughly 11,800 daltons, which means the kidneys filter it easily. Under normal circumstances, the filtering units in the kidney (glomeruli) pass B2M into the urine, and the proximal tubules reabsorb and break it down almost entirely. Very little ends up in your final urine. This cycle is why B2M levels in both blood and urine can reveal problems with the kidneys, the immune system, or both.
Normal Blood and Urine Levels
A normal serum B2M level falls between 0.70 and 1.80 mcg/mL. In urine, levels should stay at or below 300 mcg/L. When blood levels climb above this range, it signals either increased production (more cells turning over than usual) or decreased clearance (the kidneys aren’t filtering properly). Urine levels that spike suggest the proximal tubules are damaged and can no longer reabsorb B2M efficiently, even if the filtering step still works.
B2M as a Cancer Marker
B2M is most widely used in oncology for staging and monitoring blood cancers, particularly multiple myeloma and chronic lymphocytic leukemia (CLL). Cancer cells, especially those of the immune system, produce large amounts of B2M. The more cancer cells present, the higher the blood level tends to be.
Multiple Myeloma
The Revised International Staging System for multiple myeloma uses B2M as a cornerstone. The thresholds are straightforward: a level below 3.5 mg/L, combined with normal albumin and other favorable markers, places a patient in Stage I, the lowest risk category. A level between 3.5 and 5.5 mg/L corresponds to Stage II. A level above 5.5 mg/L, especially alongside certain genetic abnormalities, indicates Stage III, which carries the most guarded prognosis. These cutoffs help oncologists estimate how aggressive the disease is and guide treatment decisions from the outset.
Chronic Lymphocytic Leukemia
In CLL, B2M above 3.5 mg/L carries significant weight in the CLL International Prognostic Index, contributing the same number of scoring points as having an unmutated immunoglobulin gene, a well-established marker of more aggressive disease. Elevated B2M in CLL correlates with higher tumor burden and shorter overall survival. This association holds even in patients treated with newer targeted therapies, not just older chemotherapy regimens, making it a durable prognostic tool regardless of which era of treatment a patient receives.
Central Nervous System Lymphoma
B2M can also be measured in cerebrospinal fluid (CSF) when doctors suspect cancer has spread to or originated in the brain and spinal cord. Elevated CSF levels point toward malignant infiltration or CNS inflammation, sometimes even when tumor cells aren’t visible under the microscope. This makes B2M a helpful secondary clue when imaging and standard CSF analysis leave the diagnosis uncertain.
What B2M Reveals About Kidney Health
Because the kidneys are responsible for clearing B2M, a rising blood level can be an early sign that filtration is declining. The relationship works in the other direction too: if the tubules that line the kidney’s inner plumbing are injured, they lose the ability to reabsorb B2M, and urine levels jump. Measuring B2M in the urine can help differentiate tubular damage from glomerular damage, a distinction that matters when pinpointing the cause of kidney disease.
This kidney connection creates a practical complication for cancer staging. Patients with reduced kidney function naturally have higher B2M in their blood, which can inflate their cancer risk score. Studies in CLL patients have shown that even with compromised kidney function, B2M above 3.5 mg/L still independently predicts shorter survival. But clinicians need to interpret the number in context, especially when kidney disease and cancer coexist.
Dialysis-Related Amyloidosis
For people on long-term dialysis, B2M poses a unique problem. Standard hemodialysis doesn’t remove B2M efficiently, so blood levels gradually rise over years. Eventually, the protein can misfold and deposit as amyloid fibrils in bones, joints, and other tissues. This condition, called dialysis-related amyloidosis, typically develops after 15 or more years of dialysis. In reported cases, patients had been on dialysis for an average of 30 years at the time symptoms appeared.
The most common early sign is carpal tunnel syndrome, caused by amyloid deposits compressing the nerve at the wrist. Joint pain and stiffness, particularly in the shoulders and hips, follow. Bone cysts can develop and weaken the skeleton. Some patients experience intermittent fevers driven by inflammatory responses to the amyloid deposits. Switching to high-flux dialysis membranes or adding a B2M adsorption column to the dialysis circuit can lower B2M levels and, in some cases, reduce symptoms enough to taper anti-inflammatory medications.
Non-Cancer Causes of Elevated B2M
An elevated B2M result doesn’t automatically point to cancer. Any condition that revs up immune cell turnover will raise blood levels. Chronic infections, including HIV, are a well-known cause. Autoimmune conditions and chronic inflammatory diseases also push B2M higher because the immune system is persistently activated, shedding more of the protein from cell surfaces than usual. Chronic kidney disease, independent of any malignancy, is another common explanation. Your doctor will interpret the result alongside other lab work and your clinical picture to narrow down what’s driving the elevation.
How the Test Works
The test itself is a simple blood draw or urine collection. No fasting or special preparation is needed. Results are typically available within a few days. In cancer care, B2M is rarely used alone. It’s combined with albumin levels, genetic testing, imaging, and other bloodwork to build a complete picture. For kidney assessment, it’s paired with creatinine, estimated filtration rate, and sometimes other tubular markers to clarify where along the kidney’s filtering system the problem lies.
If your B2M comes back elevated, the next steps depend entirely on why the test was ordered. For someone being evaluated for myeloma, it feeds directly into staging. For a patient with known kidney disease, it helps track tubular function over time. For someone with unexplained symptoms, it may prompt further workup for lymphoma, autoimmune disease, or chronic infection.